Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...

The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older. Here are three things to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted approval to Azurity Pharmaceuticals ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved an expanded indication for Briviact CV tablets, oral solution and injection, for treating ...

Planning ahead for his next seizure was Brian George's daily schedule − even at work − for more than 20 years. "You adapt," he said. "You're always thinking, 'What if I have one?' You’re in a new ...

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion for Eisai's antiepileptic drug (AED) ...

Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment of partial-onset seizures (with or ...

Share on Pinterest A new drug reduced seizures in subjects with treatment resistant epilepsy in a recent clinical trial. The Good Brigade/Getty Images Researchers say a new medication may potentially ...

G400 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset G4000 Localization-related (focal) (partial) idiopathic epilepsy and epileptic ...